Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.33 |
| ▸ | ABAT | P80404 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30892256 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL30892258 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL30498483 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL27771948 | 0.82 | ERN1 (0.44) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL22492704 | 0.82 | ERN1 (0.55) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL1678698 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL29955992 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL25322018 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL10209989 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TDP1MEN1KMT2ADPP4 | |
| SCHEMBL14292712 | 0.82 | ALDH1A1 (0.46) | ALDH1A1TDP1MEN1KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447301-A | Method for preparing 2-hydroxyl 3,6-dichlorobenzoic acid | UNIV SHANGHAI OCEAN | 2015-03-25 | — | — | CN | claimed |
| CN-112299983-B | 3, 6-Dichloro salicylic acid compounds and related methods of synthesis | 孟山都技术公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-107531648-B | Herbicidal compounds | 先正达参股股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-112299983-A | 3,6-dichlorosalicylic acid compounds and related synthetic methods | 孟山都技术公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-106659162-B | 3,6-dichlorosalicylic acid compounds and related synthetic methods | 孟山都技术公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10807936-B2 | 3,6-dichlorosalicylic acid compounds and related synthetic processes | MONSANTO TECHNOLOGY LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807936-B2 | 3,6-dichlorosalicylic acid compounds and related synthetic processes | MONSANTO TECHNOLOGY LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200181055-A1 | 3,6-DICHLOROSALICYLIC ACID COMPOUNDS AND RELATED SYNTHETIC PROCESSES | MONSANTO TECHNOLOGY LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181055-A1 | 3,6-DICHLOROSALICYLIC ACID COMPOUNDS AND RELATED SYNTHETIC PROCESSES | MONSANTO TECHNOLOGY LLC (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3151670-B1 | 3,6-DICHLOROSALICYLIC ACID COMPOUNDS AND RELATED SYNTHETIC PROCESSES | MONSANTO TECHNOLOGY LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| WO-2000023433-A1 | SUBSTITUTED BENZOPYRAN ANALOGS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0977748-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
| US-5714503-A | Compounds and methods for inhibition of HIV and related viruses | MEDIVIR AB (SE) | 1998-02-03 | — | — | US | disclosed |
| US-5658907-A | THIOUREA VIRICIDES | MEDIVIR A/B (SE) | 1997-08-19 | — | — | US | disclosed |
| US-5593993-A | VIRICIDES FOR HTLV TREATMENT OF AIDS | MEDIVIR AB (SE) | 1997-01-14 | — | — | US | disclosed |
| EP-0540143-A2 | Compounds and methods for inhibition of HIV and related viruses | Medivir Aktiebolag (SE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993003022-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES | MEDIVIR AB (SE) | 1993-02-18 | — | — | WO | disclosed |
| US-4680385-A | Metal dye complexes containing an azo or azomethine dye and a colorless ligand with the C═N--N═C group | CIBA-GEIGY CORPORATION (US) | 1987-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807936-B2 | 3,6-dichlorosalicylic acid compounds and related synthetic processes | DDT, HDHD5, DDC | ALDH1A1 323/4885TDP1 1330/4885MEN1 4334/4885 |
| US-20200181055-A1 | 3,6-DICHLOROSALICYLIC ACID COMPOUNDS AND RELATED SYNTHETIC PROCESSES | DDT, HDHD5, DDC | ALDH1A1 323/4885TDP1 1330/4885MEN1 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.